Using mismatched donors for blood or bone marrow transplants is safe and could potentially lead to cures for blood cancers, Vanderbilt Health researchers found. The study, published in JAMA Network Open, compared nearly 670 patients across three studies: ACCESS trial…
Oncology
Cancer care is one of medicine’s greatest frontiers, and the institutions on this list are leading the charge. Becker’s is proud to unveil its 2026 list of hospitals and health systems recognized for excellence in oncology. This list celebrates the…
From outpatient care facilities and specialty clinics to infusion centers and research labs, here are 61 health systems opening cancer centers or expanding oncology services in 2026:
Guideline-recommended screening has changed what is possible for several cancers by helping detect cancer earlier, when it may be easier to treat. Yet too many eligible patients never enter, or remain up to date with, recommended screening. Participation rates in…
Anthem is now covering three surgical meshes for breast reconstruction, according to a clinical guideline published Aug. 27. DuraSorb Monofilament Mesh, GalaFLEX and TIGR Matrix Surgical Mesh “are considered medically necessary when used for breast reconstruction surgery,” the guidance said.…
Advertisement
The FDA has granted accelerated approval to Etcamah (camizestrant), marking the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before imaging tests show disease progression. Etcamah is used with…
An oral targeted therapy approved for pancreatic cancer showed antitumor activity in previously treated lung cancer, according to early-phase data published Sept. 2 in The New England Journal of Medicine. The drug, Rasonque (daraxonrasib), is an oral RAS inhibitor from Redwood…
Boston-based Dana-Farber Cancer Institute posted an operating loss of $9.1 million (-0.9% margin) in the third quarter of fiscal 2026, compared with an operating loss of $2.6 million (-0.3% margin) in the same quarter last year, according to its Sept.…
The FDA has approved Rasonque (daraxonrasib) for adults with advanced pancreatic cancer that has stopped responding to earlier treatment, or for patients too sick for standard combination chemotherapy. The drug improved median overall survival to 13.2 months compared with just…
The FDA has approved new first-line treatment options for adults with certain HER2-positive gastric, gastroesophageal junction and esophageal cancers. The agency approved Ziihera in combination with Tevimbra and fluoropyrimidine- and platinum-containing chemotherapy for adults with HER2-positive, unresectable, locally advanced or…